Monoclonal antibody manufacturing in transgenic plants - myths and realities
Tipo de material:
TextoSeries ; Current Opinion in Biotechnology, 13(6), p.630-635, 2002Trabajos contenidos: - Hood, E.E
- Woodard, S.L
- Horn, M.E
| Item type | Current library | Collection | Call number | Status | Date due | Barcode | |
|---|---|---|---|---|---|---|---|
Documentos solicitados
|
CICY Documento préstamo interbibliotecario | Ref1 | B-6006 (Browse shelf(Opens below)) | Available |
The number and types of antibodies expressed in plants has increased steadily since the first reports of this accomplishment in the 1980s, illustrating the versatility of plants as a production system for antibodies. Many recent reviews have detailed the antibody forms that have been derived from plant expression systems. This contribution focuses on the remaining challenges to develop plant-derived therapeutic antibodies into products, and some of the progress that is being made in addressing these challenges. Plants are proving to be a versatile system for the production of antibodies, but some challenges remain
There are no comments on this title.
